home.aspx
 
EVENTS

The Digital Pharma Advances
THE DIGITAL PHARMA ADVANCES
January 29-29, 2020
Powerfully Target & Engage HCPs & Patients & Deliver Real-World Results With Integrated, Innovative Digital Strategies.Customer-Centric, Value-Adding, Multi-Channel Digital Pharma Marketing Strategies.

4th Annual Microbiome Movement, Drug Development, Europe
4TH ANNUAL MICROBIOME MOVEMENT, DRUG DEVELOPMENT, EUROPE
February 04-05, 2020
As the first microbiome-based therapeutic steps closer to market approval, the scientific community continue to demonstrate the functional role of the human microbiome as a novel source of therapeutic, biomarker and diagnostic development. Despite this progress, the vast potential to develop effecti...

Align Biopharma

SHARESHARESHARE
Align Biopharma is an industry standards group made up of more than 20 leading pharmaceutical companies and technology and service providers that are dedicated to making it faster and easier for healthcare professionals to connect with the life sciences industry. For more information, visit AlignBiopharma.org.
SHARESHARESHARE

RELATED NEWS


Many pharmacies across the country are searching for new ways to demonstrate their value as a health care partner in a way that is manageable and cost effective. One solution could be to focus on a population that’s growing rapidly: patients with Alzheimer’s disease. By employing just a few resources and tapping into pharmacists’ existing knowledge and skills, pharmacists can become the perfect partner in the battle against Alzheimer’s disease....

READ MORE

The generic drug industry has come under fire the last couple of years because of staggering price increases. Controversies arising from the 500% hike in the generic price of the EpiPen, used to deliver epinephrine for life-threatening allergic reactions, or the 5,400% explosion in the price of Daraprim for the treatment of potentially deadly parasite infections, have only fueled price-fixing accusations....

READ MORE

Mylan’s hopes of grabbing a slice of the big US market for insulin glargine – the active ingredient in Sanofi’s Lantus blockbuster – have been dealt a blow. The FDA has issued a second complete response letter (CRL) rejecting the marketing application for the biosimilar after uncovering quality problems at Biocon – Mylan’s partner for the drug – in a pre-approval inspection of one of its manufacturing facilities in Malaysia. Biocon played down the implic...

READ MORE

Acetylsalicylic acid, best known as aspirin, and omega-3 fatty acids support various aspects of health, and scientists continue to uncover how these substances work. One recent study suggests that both could have an impact on colon cancer risk. The National Cancer Institute estimates that doctors will diagnose around 140,250 new cases of cancer of the colon and rectum in 2018 in the United States. Colon cancer develops from polyps or abnormal growths of tissue within the colon. Many of these pol...

READ MORE

This is following a positive Scientific Opinion by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), under the Early Access to Medicines Scheme (EAMS), that allows patient and doctors access to innovative treatments for serious medical conditions where there is a clear current unmet medical need, whilst they are being fully assessed for Marketing Authorisation....

READ MORE

Millions of Americans suffer from neurodegenerative diseases such as Alzheimer's and Parkinson's. Researchers have identified promising new treatments, such as cerebrolysin, but current clinical approaches are ineffective because critical concentrations of the drug dissipate within the body before reaching the blood-brain barrier and central nervous system....

READ MORE

EVENTS

The Digital Pharma Advances
THE DIGITAL PHARMA ADVANCES
January 29-29, 2020
Powerfully Target & Engage HCPs & Patients & Deliver Real-World Results With Integrated, Innovative Digital Strategies.Customer-Centric, Value-Adding, Multi-Channel Digital Pharma Marketing Strategies.

4th Annual Microbiome Movement, Drug Development, Europe
4TH ANNUAL MICROBIOME MOVEMENT, DRUG DEVELOPMENT, EUROPE
February 04-05, 2020
As the first microbiome-based therapeutic steps closer to market approval, the scientific community continue to demonstrate the functional role of the human microbiome as a novel source of therapeutic, biomarker and diagnostic development. Despite this progress, the vast potential to develop effecti...